• Revenue up 40% to $12.4m, driven by Activated Probiotics and Activated Therapeutics
• Net profit after tax up 172% to $1.18m
• Operating cash inflow of $2.09m, a $3.21m turnaround

Biome Australia Limited has reported a strong financial performance for the half-year ended 31 December 2025. Revenue increased 40% to $12.4m, driven by continued momentum across the company's Activated Probiotics range and the recently launched Activated Therapeutics. Gross margin remained strong at 61.1%. Net profit after tax for the period was $1.18m, a 172% increase on the prior corresponding period. The company generated operating cash inflow of $2.09m, a $3.21m turnaround on the prior corresponding period. Cash receipts from customers increased 62% to $13.35m, outpacing revenue growth and reflecting improved collections and working capital management. Borrowings reduced to $1.5m from $2.91m at 30 June 2025, reflecting $1.41m in net debt repayment during the half. The company held $3.36m in cash at 31 December 2025, with total current assets of $10.99m and net assets of $6.06m. Community pharmacy remains Biome's largest distribution channel, with the practitioner market also contributing meaningful growth. Internationally, the company continues to expand, with early-stage operations in Canada showing promising traction alongside growing presence in Ireland, the United Kingdom and New Zealand.

Q2 FY26 revenue of $6.48m represents an annualised run rate of approximately $25.92m exiting the half.